FDA Brief

Warning letters Drugs

FDA warning letter to

Fagron Compounding Services, LLC dba Fagron Sterile Service

High riskIssued Dec 19, 2024Posted Feb 4, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Fagron Sterile Services about unsafe sterile drug production and labeling problems at its Wichita facility.

What happened

FDA inspected the Wichita facility, registered as an outsourcing facility (a sterile compounder under section 503B), from June 18 to June 28, 2024, and issued a Form FDA 483 (inspection findings). Investigators found sterile drug production under insanitary conditions, including inadequate response to microbial contamination in the high-cleanliness (ISO 5) sterile processing area and production during construction without adequate contamination controls. FDA also found violations of required manufacturing quality rules (CGMP), labeling deficiencies, and noted the firm recalled four lots of Lidocaine HCl Injection 2% for lack of sterility assurance.

What FDA found

  1. FDA found inadequate product evaluation and corrective action after microbial contamination was recovered in the ISO 5 sterile processing area, making drugs adulterated by insanitary conditions.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  2. The firm produced drug products during construction without adequate controls to prevent contamination of the environment and products.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  3. The firm failed to thoroughly investigate unexplained discrepancies or failures of a batch or its components to meet specifications.

    21 CFR 211.192
  4. The firm failed to keep buildings used for manufacturing, processing, packing, or holding drugs clean and sanitary.

    21 CFR 211.56(a)
  5. The firm failed to establish and follow written procedures to prevent microbiological contamination of sterile drugs, including validation of aseptic and sterilization processes.

    21 CFR 211.113(b)
  6. Drug and container labels omitted required section 503B information such as dosage form, established drug name, active ingredients by established name, and directions for use.

    FDCA section 503B(a)(10) [21 U.S.C. § 353b(a)(10)]

What FDA wants

Within 15 working days of receipt, notify FDA in writing of specific corrective steps, how recurrence will be prevented, and include supporting documents; if unable to complete, state the reason and timeline.

Who should pay attention

  • hospitals and clinics that buy compounded sterile injectables
  • pharmacies and brands sourcing from outsourcing facilities
  • sterile compounders managing construction or contamination controls

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  2. Pine Pharmaceuticals, LLC

    FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.

    High risk
  3. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  4. RC Outsourcing, LLC

    FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

    High risk